TARDBP and proteostasis deficiencies: As far as we know, PROTAC 2 is the first case which can effectively degrade C-TDP-43 oligomers in addition to its protein aggregates, which provides an alternatively therapeutic strategy against TDP-43 proteinopathy in ALS.